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Resistant gonorrhoea: east meets west
In 2016 and 2018, two treatment failures of 
ceftriaxone and azithromycin, used in combination, 
were reported in the UK in men who contracted 
gonococcal infections in Asia,1,2 once again suggesting 
that antimicrobial resistance of Neisseria gonorrhoeae 
is spreading. These treatment failures indicate the 
potentially waning efficacy and usefulness of this 
combination, which is currently recommended as 
the first-line therapy. Surveillance of antimicrobial 
resistance is paramount if resistance patterns of these 
and other antimicrobials are to be recognised in a 
timely manner that enables meaningful intervention 
and prevention of the spread of resistant organisms. 
Antimicrobial susceptibility testing (phenotyping) 
for antimicrobial resistance is considered the gold-
standard test. There are some key limitations to the 
more commonly used methods of genotyping, such 
as N gonorrhoeae multi-antigen sequence typing 
(NG-MAST) and multilocus sequence typing (MLST), 
which indicate associated antimicrobial resistance 
determinants but do not directly identify antimicrobial 
resistance. The genotypes of N gonorrhoeae strains 
that are identified by use of these methods, which 
include antimicrobial resistance determinants, often 
do not correlate directly with the mean inhibitory 
concentrations of antimicrobials against these strains. 
In their Article in The Lancet Infectious Diseases, 
Simon Harris and colleagues3 used whole genome 
sequencing (WGS) for comprehensive genetic analyses 
of more than 1000 Neisseria gonorrhoeae strains 
that were isolated in 2013 in 20 European countries 
that participated in the European Gonococcal 
Antimicrobial Surveillance Programme (Euro-GASP). 
As expected, NG-MAST genogroups (designated from 
the closely related NG-MAST sequence types) fit the 
WGS phylogeny relatively well; however, separation 
into clades (the branches of the WGS phylogeny 
trees) avoided separation of clinically important, 
phylogenetically related isolates while also excluding 
phylogenetically unrelated (less relevant) isolates. 
WGS therefore maintains the breadth of analysis that 
is necessary to identify known antimicrobial resistance 
determinants and can also identify new antimicrobial 
resistance determinants. MLST and NG-MAST, 
although sensitive in their association with known 
antimicrobial resistance determinants, can be non-
specific. 
An advantage of WGS or MLST and NG-MAST over 
phenotyping is that these genotyping methods 
enable detection of modest changes to the genetic 
organisation of strains before changes to antimicrobial 
resistance (phenotypic) patterns occur; monitoring 
genes, therefore, makes for a timely sentinel-based, 
surveillance system. However, superior resolution 
of WGS versus NG-MAST and MLST, when WGS is 
linked to epidemiological data, could enable even 
earlier identification of antimicrobial resistance 
outbreaks and novel high-risk clones. Harris and 
colleagues evaluated pairwise geographical and 
cophenetic distances (phylogenetic distances between 
pairs of isolates) at the level of single nucleotide 
polymorphisms, which provided the resolution for 
comparison at the whole genome level by WGS that is 
not possible with MLST or NG-MAST. With WGS, these 
baseline comparisons showed patterns in the same 
locations, the same country, and bordering countries. 
WGS used in this manner enables recognition of 
genetic mixing as would occur in transmission 
from one of these locations to another, allowing 
identification of local hot spots or outbreaks.4,5 This 
method adds a dynamic feature to WGS, making it 
potentially capable of recognising small genomic 
changes that might be clinically or epidemiologically 
important as quickly as the sequences are generated 
and examined, almost in real time. Harris and 
colleagues also used bioinformatics6 to model evolving 
phenotypes. In this case, the authors analysed 
distribution of degree of sensitivity (susceptible, 
intermediate, and resistant) of gonococcal strains 
to three antimicrobials and, independently, sexual 
orientation of the patients, which is a novel use of WGS 
that provides information in a separate dimension.
But how do sensitive and specific genomic 
techniques inform and address the problem 
represented by the two cases with failed combined 
therapy? The NG-MAST genogroup G1407 was the 
predominant serogroup in Euro-GASP in 2013, and 
accounted for the greatest extent of cephalosporin 
resistance. However, G1407 decreased from 23% 
prevalence7 in 2009–10 to 17% in 2013 in Harris 
Published Online 
May 15, 2018 
http://dx.doi.org/10.1016/
S1473-3099(18)30276-7
See Articles page 758
iS
to
ck
/t
ha
w
or
nn
ur
ak
Comment
www.thelancet.com/infection   Vol 18   July 2018 703
and colleagues’ subsequent study. Since 2009–10, 
antimicrobial resistance patterns of N gonorrhoeae 
have changed in the EU/EEA. In 2012, combination 
therapy (ceftriaxone plus azithromycin), which was 
already being used in several countries, was officially 
recommended for all European countries.8 Cefixime 
resistance declined to 4·8%; however, azithromycin 
resistance rose to 6·7% overall,9,10 with strains 
from Cyprus and Greece together showing 28·6% 
resistance to azithromycin. Much of the antimicrobial 
resistance originates in Asia and is transmitted to 
Europe (such as in the two patients with treatment 
failure). Between 2013 and 2016, China reported a 
significant increase (from 1·9% to 3·3%) in gonococcal 
strains that showed both resistance to azithromycin 
and decreased susceptibility to ceftriaxone.11 The 
proportion of isolates with decreased susceptibility 
to ceftriaxone fluctuated between 9·7% and 12·2%, 
and the prevalence of azithromycin-resistant isolates 
was 18·6% during this period.11 Further, in eastern 
Chinese cities, resistance to azithromycin rose more 
than four-fold (from 7% to 32%) from 2008 to 2014.12 
A key step in management of antimicrobial resistance 
of gonococci in Europe will be global collaboration 
in identifying gonococcal WGSs from Asian strains, 
some of which are likely to spread to Europe. The 2017 
International Forum on Gonococcal Infections and 
Resistance, held in Shenzen in Guangdong, China, and 
led by Xiang-Sheng Chen was a crucial step forward in 
establishing these ties.13
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Eliminating cystic echinococcosis in the 21st century
Cystic echinococcosis is a helminthic disease caused by 
the larval stage of the cestode Echinococcus granulosus. 
This parasitic disease is regarded as a zoonosis because 
adult worms and eggs are found in the small intestine of 
carnivores, whereas the larval stage infects humans. As 
a definitive host, dogs play a major part in transmitting 
the infection to humans: tapeworms pass proglottids 
and eggs in dogs’ faeces and humans become infected 
through faecal-oral contact. The presence of a cyst-like 
mass in a person with a history of exposure to dogs 
in areas where E granulosus is endemic supports the 
diagnosis of cystic echinococcosis. The diagnosis can be 
made non-invasively with ultrasonography and other 
imaging techniques.1 Cystic echinococcosis is endemic 
in sheep-raising areas and is among the most neglected 
diseases in the world.2–4
The study in The Lancet Infectious Diseases by 
Francesca Tamarozzi5 and colleagues describes results 
Published Online 
May 21, 2018 
http://dx.doi.org/10.1016/
S1473-3099(18)30299-8
See Articles page 769
